Lieff Cabraser partners Brendan Glackin and Dean Harvey will be speakers at the American Antitrust Institute’s 17th Annual Private Antitrust Enforcement Conference taking place Thursday, November 2, 2023, at the National Press Club in Washington DC. The event will feature a series of panel discussions on timely topics led by experts and thought-leaders from across the antitrust community, including enforcement, advocacy, and academia.
Brendan will participate in panel discussion entitled “Big Tech: Antitrust Lessons from the Battlefield,” where he will review the status and trajectories of multiple antitrust class actions currently pending against tech giants Google, Apple, Facebook, and more.
Dean will take part in a panel entitled “Draft DOJ/FTC Merger Guidelines: Useful for Private Enforcement?” where he will review new Draft Merger Guidelines recently published by the Federal Trade Commission and the Department of Justice and discuss what they portend for private antitrust enforcement.
For more information and to register to attend, visit the AAI’s website.
About Brendan P. Glackin
The Chair of Lieff Cabraser’s Antitrust practice group, Brendan P. Glackin has represented direct purchasers of titanium dioxide in a nationwide antitrust class action lawsuit ($163.5 million in settlements); direct purchasers of flat-panel TV screens in litigation against the world’s leading LCDs manufacturers for conspiring to fix prices ($470 million in settlements; retailers in a monopolization pricing lawsuit against Abbott Laboratories charging that the company exploited the market for AIDS medicines used in conjunction with Abbott’s prescription drug Norvir, and employees in the high-tech workers class action alleging that major Silicon Valley firms colluded to reduce competition for workers.
Brendan has contributed groundbreaking work in litigation against drug makers for blocking access to affordable generics. This includes the blockbuster brand-name prescription drug Cipro ($399 million in settlements), which led to a 2016 “California Lawyer Attorney of the Year” (CLAY) award. Brendan continued his work in the field of generic drugs as lead counsel for Nashville General Hospital (the Hospital Authority of Metropolitan Government of Nashville) in a class-action antitrust case against defendants for monopolizing enoxaparin, the generic version of the blockbuster life-saving anti-coagulant Lovenox, which in 2019, settled for $120 million, the second largest indirect-purchaser antitrust pharmaceutical settlement fund in history, after Cipro.
About Dean Harvey
A partner in Lieff Cabraser’s San Francisco office, Dean M. Harvey represents individuals and companies in antitrust, business tort, employment, and intellectual property litigation. His cases seek to remedy and prevent wrongful conduct by dominant firms. These precedent-setting lawsuits concern a wide variety of industries and markets. Remedies include reimbursing purchasers who have overpaid for price-fixed products; preventing monopolists from stifling innovation and eliminating competition; and obtaining damages for businesses, inventors, and copyright owners.
Mr. Harvey was a leader in the High-Tech Antitrust class action against Google, Apple, Intel and other tech giants for allegedly conspiring to suppress the mobility and compensation of their technical employees. This landmark case resulted in the largest recovery (by far) of any class action asserting antitrust claims in the employment context: $435 million. Mr. Harvey continues the fight to ensure that employees receive competitive compensation, currently representing a doctor in a class action alleging an unlawful no-hire agreement between the medical schools of Duke University and the University of North Carolina